Poor
Not Aligned
Patient Risk:
Low
Summary
Only one of three claims is supported by the provided label excerpt (active ingredients). The other two claims (manufacturer and U.S. marketing entity) are not verifiable from the supplied FDA label section.
Category Scores
Accurate Statements
Orkambi contains two active ingredients: lumacaftor and ivacaftor.
Label Section 11 (DESCRIPTION) states the active ingredients in ORKAMBI tablets are lumacaftor and ivacaftor.
Unsupported Statements
Orkambi (lumacaftor/ivacaftor) is manufactured by AbbVie.
The provided label excerpt (Section 11 DESCRIPTION) does not mention manufacturing or AbbVie.
AbbVie markets Orkambi in the U.S.
The provided label excerpt (Section 11 DESCRIPTION) does not mention marketing or a U.S. marketing entity.
Contradictions
Important Omissions
No label comparison was performed for safety-critical or dosing elements because only Section 11 (DESCRIPTION) content was provided/examined.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The verifiable claim is limited to active ingredients; unverified manufacturer/marketing claims are not, by themselves, patient-safety determinants in the provided excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Two claims (manufacturer and U.S. marketing entity) are not supported by the provided FDA label section excerpt.
Suggested Improvement
Remove or qualify the manufacturer/marketing claims unless additional FDA label sections (e.g., manufacturer/distributor or how supplied/storage/handling) are provided to support them; keep only the claim supported by Section 11 (active ingredients: lumacaftor and ivacaftor).